Case Report

Erythrodermic Psoriasis Causing Uric Acid Crystal Nephropathy

John Ellis,1 Jeffrey Lew,1 Sumir Brahmbhatt,1,2 Sarah Gordon,1,2 and Troy Denunzio1,2

1Department of Medicine, Tripler Army Medical Center, Honolulu, HI, USA
2Nephrology Service, Tripler Army Medical Center, Honolulu, HI, USA

Correspondence should be addressed to Sumir Brahmbhatt; brahmbhatt@gmail.com

Received 18 September 2018; Accepted 11 February 2019; Published 28 March 2019

Academic Editor: Walter Zidek

Copyright © 2019 John Ellis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Erythrodermic psoriasis is a rare and severe variant of psoriasis. It is characterized by widespread skin erythema, scaling, pustules, or exfoliation of more than 75% of the body’s surface area [1]. There are multiple documented and emerging causes of EP. The main risk factors are history of psoriasis and medications. In a retrospective review of 50 patients with EP, the mean time of diagnosis of psoriasis to EP flare was 14 years and rarely was EP, the presenting symptom for psoriasis diagnosis [2]. In addition, there is a relationship between EP and starting certain medications including drugs used to treat psoriasis. It has been well documented that starting oral or topical corticosteroids for psoriasis can cause an EP flare as can abruptly discontinuing corticosteroids for treatment of psoriasis [2]. Similarly, the use of biologics has been reported as causing EP in patients being treated for psoriasis and Crohn’s disease [3, 4], and there are several case reports of abrupt cessation of biologic agents precipitating EP [5, 6].

EP has life-threatening complications to include hemodynamic, metabolic, immunologic, infectious, and thermoregulatory disturbances. The erythroderma causes exfoliative dermatitis of the skin, shedding the epidermis and increasing the risk of Staphylococcus aureus septicemia [7].

1. Background

Erythrodermic psoriasis (EP) is a rare and severe variant of psoriasis that occurs in 1-2% of affected patients. It is characterized by widespread skin erythema, scaling, pustules, or exfoliation of more than 75% of the body’s surface area [1]. There are multiple documented and emerging causes of EP. The main risk factors are history of psoriasis and medications. In a retrospective review of 50 patients with EP, the mean time of diagnosis of psoriasis to EP flare was 14 years and rarely was EP, the presenting symptom for psoriasis diagnosis [2]. In addition, there is a relationship between EP and starting certain medications including drugs used to treat psoriasis. It has been well documented that starting oral or topical corticosteroids for psoriasis can cause an EP flare as can abruptly discontinuing corticosteroids for treatment of psoriasis [2]. Similarly, the use of biologics has been reported as causing EP in patients being treated for psoriasis and Crohn’s disease [3, 4], and there are several case reports of abrupt cessation of biologic agents precipitating EP [5, 6].

EP has life-threatening complications to include hemodynamic, metabolic, immunologic, infectious, and thermoregulatory disturbances. The erythroderma causes exfoliative dermatitis of the skin, shedding the epidermis and increasing the risk of Staphylococcus aureus septicemia [7].
The generalized inflammation of the skin causes vasodilation and subsequent thermoregulatory disturbances. The shunting of the blood combined with the exfoliative losses causes increased transpiration and fluid losses proportional to the surface area involved. As a result of the fluid losses and shunting, there are multiple electrolyte abnormalities and organ hypoperfusion effects that can occur. One metabolic complication that has been reported in EP is hyperuricemia, which has both acute and chronic components. Chronically elevated uric acid occurs from rapid abnormal keratinocyte differentiation and infiltration of inflammatory cells into psoriatic lesions. These lead to increased cell turnover and nucleic acid breakdown [8]. Additionally, psoriasis itself can cause immune-related IgA deposits from T-cell activation and tumor necrosis factor-α production causing psoriatic nephropathy [9]. EP can be associated with acute kidney injury from medications or hypoperfusion as described above which can reduce the clearance of uric acid.

With multiple acute on chronic causes of hyperuricemia, there are no reports of EP causing crystal-induced nephropathy. The most common causes of uric acid nephrolithiasis include primary gout, gastrointestinal disorders, neoplastic disorders, diet, and sometimes inherited metabolic abnormalities [10, 11]. We present a unique case of erythrodermic psoriasis and hyperuricemia complicated by uric acid crystal nephropathy and acute kidney injury.

2. Case Presentation

A 57-year-old male from Thailand with long-standing psoriatic arthritis presented with diffuse scaling of his skin. He was being treated for psoriatic arthritis with adalimumab, leflunomide, and topical clobetasol, but had stopped taking all medications two weeks prior to presentation. At baseline, the patient was a gardener and able to complete all his activities of daily living. However, during the disease course, he noticed diffuse skin scaling and had diarrhea, leading to fatigue. His only joint complaint was chronic left ankle pain, and he denied oral ulcers. Physical exam revealed diffuse yellow scaling covering his entire body with underlying erythema and tenderness without mucosal involvement (Figures 1(a) and 1(b)). Empiric antibiotics were started until blood cultures ruled out infection. Labs were notable for a creatinine of 3.3 mg/dL, with no prior history of renal disease, calcium 7.8 mg/dL, phosphate 5.9 mg/dL, bicarbonate 13.0 mmol/L, urine pH 5.0, and uric acid of 12.7 mg/dL (Table 1). The patient was admitted to the intensive care unit given >80% of body surface area involvement and acute renal failure. He received 4 L of normal saline for initial resuscitation. On day 2, the patient was determined to be euvolemic based on clinical exam with moist mucous membranes. Despite aggressive fluid administration, renal function did not improve, and creatinine continued to rise and peaked at 4.61 mg/dL, with phosphate of 7.0 mg/dL and 48 hours of anuria. Renal ultrasound showed 5 mm nonobstructing renal calculi in the left kidney and small echogenic kidneys consistent with chronic kidney disease (Figure 1(c)). Subsequent urine microscopy showed diffuse polymorphic uric acid crystals, consistent with uric acid crystal-induced nephropathy (Figure 1(d)). He was managed with rasburicase, urinary alkalinization, and fluids. The underlying erythrodermic psoriasis was treated with restarting leflunomide, topical isotretinoin, and clobetasol. His renal function improved dramatically; urine output, uric
acid, and electrolytes normalized. He was discharged on topical clobetasol and leflunomide and new addition of secukinumab with little to no skin involvement.

3. Conclusions

Uric acid crystal-induced nephropathy is a rare complication of severe erythrodermic psoriasis. Although hyperuricemia has been reported in patients with psoriasis, uric acid-induced crystal nephropathy has not been reported in the setting of EP. In a study comparing uric acid levels in different types of psoriasis, EP had the highest serum uric acid levels and serum creatinine compared to psoriasis vulgaris and generalized pustular psoriasis [12]. However, the exact etiology for this hyperuricemia is unknown. In our case, it is thought to be due to a multifactorial process that caused uric acid elevation from the psoriasis and renal failure. Psoriasis has increased infiltration of inflammatory cells in addition to rapid cellular turnover producing a tumor lysis syndrome-like picture [13]. The patient’s renal failure was likely due to prerenal azotemia from decreased oral intake, diarrhea and fluid losses from his skin resulting decreasing the excretion of uric acid and production of urine resulting in a microenvironment ideal for uric acid nephrolithiasis.

Treatment of EP with uric acid-induced nephrolithiasis includes both treating the underlying EP and treatment of the uric acid nephrolithiasis. For EP, treatment is difficult because there are no large double-blind placebo-controlled randomized trials due to low incidence. Through non-randomized controlled trials and case series, first-line treatment for EP includes cyclosporine, infliximab, topical retinoids and methotrexate, and supportive management [1]. However, each of these agents should be used with extreme caution. Recognizing uric acid nephrolithiasis and acute kidney injury influences selection of EP treatment because cyclosporine and methotrexate should be avoided in patients with CrCl <30 ml/min. In addition, cyclosporine has been documented numerous times to increase serum uric acid levels which can exacerbate uric acid nephrolithiasis [14]. Selection of infliximab should also be used with caution because Staphylococcus aureus infection can both precipitate and exacerbate EP flares as immunosuppression would put patients at greater risk for septicemia [7, 15].

Uric acid-induced nephropathy treatment was individualized for this patient’s underlying hyperuricemia to include aggressive fluid resuscitation, urine alkalinization, and uric acid lowering agents. Although uric acid nephrolithiasis can be treated with macromolecular inhibitors of crystallization such as rasburicase, and pegloticase, it has been mostly studied in patients with tumor lysis syndrome specifically in childhood leukemias and lymphoma [16]. These medications have not been studied in the context of

| Table 1: Presenting labs. |
|--------------------------|
| **Initial studies**       | **Presentation** | **Hospital day 3** |
| Na                       | 138             | 135             |
| K                        | 5.1             | 4.6             |
| Cl                       | 110             | 100             |
| HCO₃⁻                    | 13              | 18              |
| BUN                      | 37              | 38              |
| Cr                       | 3.30 H          | 4.61 H          |
| Glucose                  | 69              | 231             |
| Ca                       | 7.8 (L)         | 7.6 (L)         |
| Mg                       | 1.5             | 2.0             |
| P                        | 5.9 (H)         | 5.9 (H)         |
| Alb                      | 2.0 (L)         | 2.1 (L)         |
| **Basic metabolic panel**|                 |                 |
| Color Appearance         | Yellow Hazy     | Yellow Hazy     |
| SG                       | 1.018 (1.003–1.030) | 1.020 (1.003–1.030) |
| pH                       | 5.0 (4.5–8.0)   | 5.0 (4.5–8.0)   |
| Protein                  | +1 (H) (negative) | Protein +1 (H) (negative) |
| Ketones                  | Trace           | Ketones Trace   |
| Bilirubin                | Negative (negative) | Bilirubin Negative (negative) |
| Urobiligen               | Normal (0.2–1.0) mg/dL | Urobiligen Normal (0.2–1.0) mg/dL |
| UA blood                 | +2 (negative)   | UA blood +2 (negative) |
| Leuk                     | Est negative    | Leuk est +2 (H) |
| RBC UA                   | 10 (H) (0–5)/HPF | RBC UA 10 (H) (0–5)/HPF |
| WBC                      | 6 (H) (0–5)/HPF | WBC 6 (H) (0–5)/HPF |
| Bacteria                 | Rare            | Bacteria Rare   |
| Squamous cells           | 2               | Squamous cells 2 |
| Urinary eosinophils       | Negative        |                 |

Renal ultrasound  Left kidney 9 cm and lower pole renal calculi 5 mm nonobstructing. Right kidney 8 cm renal cortices echogenic bilaterally consistent with medical renal disease.
hyperuricemia from EP. However, due to the rapidity and severity of symptoms and electrolyte abnormalities similar to tumor lysis syndrome, our patient was treated with rasburicase with clinical and laboratory improvement.

It is critical for providers to suspect hyperuricemia and uric acid-induced nephrolithiasis when a patient presents with EP. Treatment should be individualized to the patient, and if renal function does not improve after fluid resuscitation, there should be a low threshold for continued workup to include renal ultrasound, urine microscopy, and serial electrolyte panels, as well as initiation of a uric acid lowering agent such as rasburicase since the patient is at high risk for progression to life-threatening complications and progression to kidney failure.

Abbreviations

EP: Erythrodermic psoriasis
FENa: Fractional excretion of sodium.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Disclosure

An earlier version of this manuscript was presented as a poster at the 2018 Hawaii ACP Annual Meeting in Honolulu, Hawaii. This can be found at https://www.acponline.org/system/files/documents/about_acp/chapters/ga/2018_acp_hawaii_program_book_.pdf.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Dr. John Ellis drafted the manuscript and was a resident on duty in the ICU for this case. Dr. Jeff Lew revised the manuscript. Dr. Sumir Brahmbhatt was a resident on nephrology service for this case and revised the manuscript. Dr. Sarah Gordon provided guidance on the manuscript drafting and edited the draft. Dr. Troy Denunzio was a resident on nephrology service and attended on this case initially.

Acknowledgments

The authors of this paper would like to acknowledge Dr. Joseph Roswarski for his assistance on this manuscript. Funding for publication of this manuscript will be provided for the host institution.

References

[1] M. Rosenbach, S. Hsu, N. J. Korman et al., “Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation,” Journal of the American Academy of Dermatology, vol. 62, no. 4, pp. 655–662, 2010.
[2] A. S. Boyd and A. Menter, “Erythrodermic psoriasis,” Journal of the American Academy of Dermatology, vol. 21, no. 5, pp. 985–991, 1989.
[3] E. Shmidt, D. A. Wetter, S. B. Ferguson, and M. R. Pittelkow, “Psoriasis and panniculitis: a review of psoriasis proliferation factor-a inhibitors: the Mayo clinic experience, 1998 to 2010,” Journal of the American Academy of Dermatology, vol. 67, no. 5, pp. e179–e185, 2012.
[4] R. Goiriz, E. Daudèn, S. Pérez-Gala, G. Guhl, and A. García-Diez, “Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers,” Clinical and Experimental Dermatology, vol. 32, no. 2, pp. 176–179, 2007.
[5] K. A. Potter, K. Motaparthi, J. J. Schoch, and J. J. Schoch, “Erythrodermic psoriasis after discontinuation of ixekizumab,” JAAD Case Reports, vol. 4, no. 1, pp. 22–23, 2018.
[6] E. N. Kop, J. E. M. Körver, D. Van Ruyssevelt et al., “Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment,” Journal of Dermatological Treatment, vol. 20, no. 1, pp. 67–69, 2009.
[7] J. H. Prystowsky and P. R. Cohen, “Pustular and erythrodermic psoriasis,” Dermatologis Clinics, vol. 13, no. 4, pp. 757–770, 1995.
[8] X. Li, X. Miao, H. Wang et al., “Association of serum uric acid levels in psoriasis: a systematic review and meta-analysis,” Medicine, vol. 95, no. 19, 2016.
[9] N. P. Singh, A. Prakash, S. Kubba et al., “Psoriatic nephropathy does an entity exist?,” Renal Failure, vol. 27, no. 1, pp. 123–127, 2005.
[10] J. Trachsel, A. Gaspert, M. Previsdomini, R. P. Wuthrich, and T. Fehr, “Massive uric acid nephrolithiasis with progressive renal failure due to spontaneous tumour lysis syndrome,” Clinical Kidney Journal, vol. 1, no. 5, pp. 307–309, 2008.
[11] M. R. Wiederkehr and O. W. Moe, “Uric acid nephrolithiasis: a systemic metabolic disorder,” Clinical Reviews in Bone and Mineral Metabolism, vol. 9, no. 3–4, pp. 207–217, 2011.
[12] Y. Hu, L. W. Yin, J. Xu, and Z. Yin, “Renal function of psoriatic patients: erythrodermic psoriasis has more significant hyperuricemia,” Journal of the American Academy of Dermatology, vol. 21, no. 5, pp. 141–146, 1992.
[13] A. Z. Eisen and J. E. Seegmiller, “Uric acid metabolism in psoriasis,” Journal of Clinical Investigation, vol. 40, no. 8, pp. 1486–1494, 1961.
[14] D. A. Burack, B. P. Griffith, M. E. Thompson, and L. E. Kahl, “Hyperuricemia and gout among heart transplant recipients receiving cyclosporine,” American Journal of Medicine, vol. 92, no. 2, pp. 141–146, 1992.
[15] M. S. Green, J. H. Prystowsky, S. R. Cohen, J. I. Cohen, and M. G. Lebwohl, “Infectious complications of erythrodermic psoriasis,” Journal of the American Academy of Dermatology, vol. 34, no. 5, pp. 911–914, 1996.
[16] S. C. Goldman, J. S. Holcenberg, J. Z. Finklestein et al., “A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis,” Blood, vol. 97, no. 10, pp. 2998–3003, 2001.